Randomized comparative trial with ceftizoxime and cefotaxime in urinary tract infections

Abstract

Ceftizoxime, a new, semisynthetic, beta-lactamase-resistant cephalosporin, is not metabolized in man and is excreted almost entirely as the original active compound in the urine. The efficacy and safety of ceftizoxime were assessed in 80 patients with acute and chronic urinary infections, with and without associated pathological conditions, in comparison with cefotaxime. Two dosage schedules, 1 g or 0.5 g every 12 h, i.v. or i.m. for 10 days, were adopted according to the severity of each case and to separate randomization tables for each schedule; causal agents were all sensitive to both drugs in vitro. The overall results were excellent. Safety was excellent in almost all cases. In this trial ceftizoxime proved at least as effective and well tolerated as the reference antibiotic.

A Meta‐Analysis of Randomized, Controlled Trials Assessing the Prophylactic Use of Ceftriaxone. A Study of Wound, Chest, and Urinary Infections

“…1. After triage, there were 90 remaining studies that were included in the meta‐analysis [6–9, 12–96]. Of these 44 were sourced from Medline, an additional 8 from Embase, 10 from the Cochrane registers, 10 from scientific meetings, and 18 from identified references.…”

“…The comparison between ceftriaxone and other antibiotics in reducing urinary tract infections was analyzed in 44 studies ( n = 14,907 patients) [6–9, 13, 15, 17, 20, 23–27, 30, 36, 37, 39, 41, 43, 46–51, 55, 57, 62, 63, 65, 67–69, 71–82]. The funnel plot identified three studies [49, 74, 78] that were on or outside the 95% confidence interval, two [74 78] in favor of ceftriaxone.…”

“…These three studies were excluded from further analysis. Six studies [50, 72, 76, 80–82] assessed the ability of antibiotics to reduce UTI after endoscopic surgery. These showed a difference in favor of ceftriaxone (OR 0.77; 95% CI 0.51–0.99; p = 0.04).…”